11 results on '"Davide Topazio"'
Search Results
2. Inactivation of human salivary glutathione transferase P1-1 by hypothiocyanite: a post-translational control system in search of a role.
- Author
-
Raffaele Fabrini, Alessio Bocedi, Serena Camerini, Marco Fusetti, Fabrizio Ottaviani, Francesco M Passali, Davide Topazio, Federica Iavarone, Irene Francia, Massimo Castagnola, and Giorgio Ricci
- Subjects
Medicine ,Science - Abstract
Glutathione transferases (GSTs) are a superfamily of detoxifying enzymes over-expressed in tumor tissues and tentatively proposed as biomarkers for localizing and monitoring injury of specific tissues. Only scarce and contradictory reports exist about the presence and the level of these enzymes in human saliva. This study shows that GSTP1-1 is the most abundant salivary GST isoenzyme, mainly coming from salivary glands. Surprisingly, its activity is completely obscured by the presence of a strong oxidizing agent in saliva that causes a fast and complete, but reversible, inactivation. Although salivary α-defensins are also able to inhibit the enzyme causing a peculiar half-site inactivation, a number of approaches (mass spectrometry, site directed mutagenesis, chromatographic and spectrophotometric data) indicated that hypothiocyanite is the main salivary inhibitor of GSTP1-1. Cys47 and Cys101, the most reactive sulfhydryls of GSTP1-1, are mainly involved in a redox interaction which leads to the formation of an intra-chain disulfide bridge. A reactivation procedure has been optimized and used to quantify GSTP1-1 in saliva of 30 healthy subjects with results of 42±4 mU/mg-protein. The present study represents a first indication that salivary GSTP1-1 may have a different and hitherto unknown function. In addition it fulfills the basis for future investigations finalized to check the salivary GSTP1-1 as a diagnostic biomarker for diseases.
- Published
- 2014
- Full Text
- View/download PDF
3. Unusual Postrhinoplasty Complication: Nasal Dorsum Cyst
- Author
-
Pier Giorgio Giacomini, Davide Topazio, Roberta Di Mauro, Stelio Mocella, Matteo Chimenti, and Stefano Di Girolamo
- Subjects
Otorhinolaryngology ,RF1-547 - Abstract
Among all the possible complications of aesthetic rhinoplasty, a rare one is the development of cystic masses on the nasal dorsum: several theories suggest that cysts develop commonly by entrapment of nasal mucosa in the subcutaneous space, but they can also originate from foreign body reactions. This report deals with two cases of nasal dorsum cysts with different pathogenesis: both patients had undergone aesthetic rhinoplasty in the past (26 years ago and 14 years ago, resp.). Both cystic masses were removed via a direct open approach and nasal reconstruction was performed successfully with autologous vomer bone. The pathologic investigations showed a foreign body inclusion cyst associated with latex rubber in the first case and a sequestration of a mucosal-lined nasal bone was not removed at the time of primary rhinoplasty in the second case. A brief review of the literature focuses on the pathophysiology and treatment options for nasal dorsal cysts following aesthetic rhinoplasty.
- Published
- 2014
- Full Text
- View/download PDF
4. Dichotomous metabolic networks govern human ILC2 proliferation and function
- Author
-
Carys A. Croft, James P. Di Santo, Antonia Cama, Solenne Marie, Carmen Buchrieser, Davide Topazio, Olimpia Musumeci, Valerie Dardalhon, Laura Surace, Naomi Taylor, Jean-Marc Doisne, Vincent Guillemot, Natalia Petrosemoli, Pedro Escoll, Ido Amit, Anna Thaller, Immunité Innée - Innate Immunity, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), École Doctorale Bio Sorbonne Paris Cité [Paris] (ED562 - BioSPC), Université Sorbonne Paris Cité (USPC)-Université Paris Cité (UPCité), Biologie des Bactéries intracellulaires - Biology of Intracellular Bacteria, Université Paris Cité (UPCité)-Microbiologie Intégrative et Moléculaire (UMR6047), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hub Bioinformatique et Biostatistique - Bioinformatics and Biostatistics HUB, Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Department of Otolaryngology, Ospedale 'Giuseppe Mazzini' di Teramo, Department of Maxillofacial and Otolaryngology, Hospital 'Floraspe Renzetti', Department of Immunology [Rehovot, Israël], Weizmann Institute of Science [Rehovot, Israël], Department of Clinical and Experimental Medicine [Messina, Italy], University of Messina, The Innate Immunity Unit is supported by grants from the Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur, the Agence National pour le Recherche (ANR) and the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (695467, ILC_REACTIVITY). A.T. is supported by European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 765104. C.B.’s group was supported by the Fondation pour la Recherche Médicale (FRM) grant no. EQU201903007847 and the grant no. ANR-10-LABX-62-IBEID. L.S. was supported by an SNSF-Early PostDoc. Mobility fellowship and a Marie Curie grant (H2020- MSCA-IF-2017)., We thank all the members of the Innate Immunity Unit for helpful discussions, the Centre de Recherche Translationnelle and the logistic department of Institut Pasteur. We thank the CB-UTechS platform for cytometry support and the Imagopole-CiTech (part of France-BioImaging supported by ANR grant no. ANR-10-INSB-04-01, Conseil de la Region Ile-de-France, FRM) for technical support., The study was conceptualized by L.S. and J.P.D. Experiments were coordinated by L.S. FACS and subsequent analyses were performed by L.S., C.A.C., A.T., J.-M.D. and S.M. Confocal microscopy analysis was performed by P.E., C.B. and L.S. Bioinformatic analyses were performed by N.P. and V.G. RNA-seq experiments were conducted by I.A. O.M., V.D., N.T., D.T. and A.C. provided resources. L.S. and J.P.D. wrote the paper. Funding was acquired by L.S. and J.P.D., and the study was supervised by J.P.D., ANR-10-INBS-0004,France-BioImaging,Développment d'une infrastructure française distribuée coordonnée(2010), ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), European Project: 695467,H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) ,ILC_REACTIVITY(2016), European Project: 765104,MATURE-NK, European Project: 796004,BIF-SCV, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), École Doctorale Bio Sorbonne Paris Cité [Paris] (ED BioSPC), Université Sorbonne Paris Cité (USPC)-Université de Paris (UP), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), and Hospital 'Giuseppe Mazzini'
- Subjects
Letter ,Mitochondrial Diseases ,Lymphocyte Activation ,0302 clinical medicine ,Immunology and Allergy ,Glycolysis ,Receptor ,Tissue homeostasis ,Cells, Cultured ,0303 health sciences ,MESH: Cytokines ,Innate lymphoid cell ,MESH: Energy Metabolism ,MESH: Arginine ,MESH: Mitochondrial Diseases ,MESH: Case-Control Studies ,Cell biology ,Mitochondria ,Phenotype ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Cytokines ,MESH: Immunity, Innate ,MESH: Cells, Cultured ,MESH: Interleukin-33 ,MESH: Mitochondria ,Immunology ,Innate lymphoid cells ,Oxidative phosphorylation ,Biology ,MESH: Phenotype ,Arginine ,03 medical and health sciences ,Th2 Cells ,MESH: Th2 Cells ,MESH: Cell Proliferation ,Humans ,MESH: Lymphocyte Activation ,PI3K/AKT/mTOR pathway ,030304 developmental biology ,Cell Proliferation ,MESH: Humans ,Interleukins ,Metabolism ,Interleukin-33 ,Immunity, Innate ,Metabolic pathway ,Case-Control Studies ,Energy Metabolism ,Amino Acids, Branched-Chain ,030215 immunology ,MESH: Amino Acids, Branched-Chain - Abstract
Group 2 innate lymphoid cells (ILC2s) represent innate homologs of type 2 helper T cells (TH2) that participate in immune defense and tissue homeostasis through production of type 2 cytokines. While T lymphocytes metabolically adapt to microenvironmental changes, knowledge of human ILC2 metabolism is limited, and its key regulators are unknown. Here, we show that circulating ‘naive’ ILC2s have an unexpected metabolic profile with a higher level of oxidative phosphorylation (OXPHOS) than natural killer (NK) cells. Accordingly, ILC2s are severely reduced in individuals with mitochondrial disease (MD) and impaired OXPHOS. Metabolomic and nutrient receptor analysis revealed ILC2 uptake of amino acids to sustain OXPHOS at steady state. Following activation with interleukin-33 (IL-33), ILC2s became highly proliferative, relying on glycolysis and mammalian target of rapamycin (mTOR) to produce IL-13 while continuing to fuel OXPHOS with amino acids to maintain cellular fitness and proliferation. Our results suggest that proliferation and function are metabolically uncoupled in human ILC2s, offering new strategies to target ILC2s in disease settings., ILC2 metabolism has been largely unexplored. Di Santo and colleagues examine metabolic profiles from naive and cytokine-activated ILC2s and find that IL-33-triggered ILC2s rely on distinct metabolic pathways to sustain proliferation and function.
- Published
- 2021
- Full Text
- View/download PDF
5. Anatomic landmarks for masseteric nerve identification: Anatomic study for a new reference point
- Author
-
Teodoro Aragona, Davide Topazio, Alfonso Manfuso, Chiara Copelli, Antonia Cama, and Bernhard Hirt
- Subjects
Male ,medicine.medical_specialty ,Masseteric nerve ,Mandibular Nerve ,Patient characteristics ,Anatomic landmark ,Facial nerve ,Facial reanimation ,Zygomatic branch ,030230 surgery ,03 medical and health sciences ,0302 clinical medicine ,stomatognathic system ,Cadaver ,medicine ,Humans ,Zygoma ,Masseter Muscle ,business.industry ,Dissection ,Anatomy ,medicine.disease ,Facial paralysis ,Surgery ,Anatomical landmark ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Female ,Zygomatic arch ,Anatomic Landmarks ,Cadaveric spasm ,business - Abstract
The masseteric nerve is often used as a donor nerve in the treatment of facial paralysis. Even if several anatomical studies described landmarks for its identification, their main disadvantages are the anatomical variability and the changes due to surgery. Sixteen dissections were performed on cadaveric specimens. The masseteric muscle (MM), the zygomatic arch (ZA), the masseteric nerve (MN) and the zygomatic branch of the facial nerve (ZB) were identified and their relationships were measured. The relationships between MN and ZB resulted to be constant, with MN intersecting ZB at a depth of 0,78 cm in the muscle, 1,6 cm below ZA and 0,8 cm from the posterior border of MM. The measures obtained demonstrated as the main zygomatic branch of the facial nerve can be a suitable landmark for the identification of the masseteric nerve, with no variations due to the surgical procedure or patient characteristics.
- Published
- 2021
6. Impact of COVID-19 pandemic on Italian Otolaryngology Units: a nationwide study
- Author
-
Gabriele Molteni, Pierre Guarino, Alfonso Scarpa, Pasquale Capasso, Marco Bonali, Massimo Ralli, Davide Topazio, Russo G, Giuditta Mannelli, Giacomo Spinato, Niccolò Mevio, and Valeria Iannini
- Subjects
COVID-19, otolaryngology, SARS-CoV-2, pandemic ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,COVID-19 ,Otolaryngology ,SARS-CoV-2 ,Pandemic ,Personnel Staffing and Scheduling ,Workload ,03 medical and health sciences ,0302 clinical medicine ,otolaryngology ,pandemic ,Surveys and Questionnaires ,Medicine ,Humans ,Mass Screening ,Practice Patterns, Physicians' ,030223 otorhinolaryngology ,Pandemics ,Mass screening ,Infection Control ,business.industry ,pandemia ,otolaringoiatria ,General Energy ,Otorhinolaryngology ,Italy ,030220 oncology & carcinogenesis ,business ,Humanities - Abstract
The aim of this study was to provide an accurate picture of the changes which have occurred during the COVID-19 pandemic, and the contributions given by Italian Otolaryngology Units.A 29-item questionnaire was completed and returned by 154 Otorhinolaryngology Units across Italy that investigated geographic distribution, the main changes which occurred in workload management and in clinical and surgical activities and screening procedures for COVID-19 in healthcare personnel and patients.Nearly half of the Otolaryngology Units that responded to the questionnaire were merged with other units, while 22% were converted into COVID-19 units or temporarily closed. A reduction of 8.55% in the number of team members was reported, and about 50% of the units applied uniform work shifts for all staff. Elective activities were uniformly stopped or delayed, passing from 30,295 (pre-COVID data) to 5,684 (COVID data) weekly procedures, with a mean decrease of 81.24% (p0.001).Most of the elective otolaryngology activities were suspended during the pandemic; the only procedures were for oncology and emergency patients. Italian Otolaryngologists have demonstrated a high availability to collaborate with non-surgical colleagues.Impatto della pandemia COVID-19 sulle Unità Operative di Otorinolaringoiatria in Italia: uno studio nazionale.Fornire un quadro accurato dei cambiamenti che si sono verificati e dei contributi forniti dalle Unità di Otorinolaringoiatria italiane durante la pandemia COVID-19.Un questionario di 29 domande è stato completato da 154 unità. Sono stati investigati la distribuzione geografica del loro coinvolgimento, i cambiamenti di gestione del carico di lavoro e delle attività clinico-chirurgiche e le procedure di screening applicate su personale sanitario e pazienti.Quasi la metà delle Unità che hanno risposto sono state fuse con altre unità operative, mentre il 22% è stato convertito in unità COVID-19 o temporaneamente chiuso. È stata segnalata una riduzione dell’8,55% nel numero dei membri del gruppo di lavoro e circa il 50% dei dipartimenti ha applicato turni di lavoro per tutto il personale. Tutte le attività elettive sono state uniformemente interrotte o ritardate, passando da 30.295 (dati pre-COVID) a 5.684 (dati COVID) procedure settimanali, con una diminuzione media dell’81,24% (p0,001).La maggior parte delle attività elettive in otorinolaringoiatria, a parte le procedure oncologiche e di emergenza, sono state sospese. Gli otorinolaringoiatri italiani hanno dimostrato un’alta disponibilità a collaborare con i reparti di medicina.
- Published
- 2020
7. Tinnitus and equilibrium disorders in COVID-19 patients: preliminary results
- Author
-
Giuseppe Chiarella, Pasquale Viola, Alfonso Scarpa, Davide Topazio, Lucio Cosco, Massimo Ralli, Domenico Sculco, G. Leopardi, Carla Laria, Davide Pisani, Viviana Vespertini, Elio Maria Cunsolo, Teodoro Aragona, Donatella Malanga, Francesco Quintieri, Antonia Cama, Francesco Ursini, Luigi Messina, Viola, P., Ralli, M., Pisani, D., Malanga, D., Sculco, D., Messina, L., Laria, C., Aragona, T., Leopardi, G., Ursini, F., Scarpa, A., Topazio, D., Cama, A., Vespertini, V., Quintieri, F., Cosco, L., Cunsolo, E. M., Chiarella, G., Viola P., Ralli M., Pisani D., Malanga D., Sculco D., Messina L., Laria C., Aragona T., Leopardi G., Ursini F., Scarpa A., Topazio D., Cama A., Vespertini V., Quintieri F., Cosco L., Cunsolo E.M., and Chiarella G.
- Subjects
Tinnitu ,Pediatrics ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Otology ,Dizziness ,Vestibular disorders ,03 medical and health sciences ,Tinnitus ,COVID-19 Testing ,0302 clinical medicine ,Vertigo ,otorhinolaryngologic diseases ,medicine ,Humans ,In patient ,030223 otorhinolaryngology ,COVID-19 ,Screening ,biology ,SARS-CoV-2 ,Dizzine ,business.industry ,Balance disorders ,General Medicine ,medicine.disease ,biology.organism_classification ,Otorhinolaryngology ,Migraine ,030220 oncology & carcinogenesis ,Neurosurgery ,medicine.symptom ,business - Abstract
Purpose: Tinnitus and equilibrium disorders such as dizziness and vertigo have been reported by patients with COVID-19; however, they have been rarely investigated. The aim of this study was to study the prevalence of subjective tinnitus and dizziness in a sample of COVID-19 patients using an online 10-item close-ended questionnaire. Methods: A multicentric study that included 15 Italian hospitals in different regions was conducted using an online 10-item close-ended questionnaire developed to identify the presence of tinnitus and balance disorders in patients with COVID-19 between May 5 and June 10, 2020. The questionnaire was administered to 185 patients in a period of > 30 – < 60days after diagnosis of COVID-19; responses were recorded in an online Excel spreadsheet. The questionnaire was composed of three sections: (1) demographic information; (2) presence and characteristics of tinnitus and dizziness after COVID-19 diagnosis; (3) possible association with migraine. Results: Thirty-four patients (18.4%) reported equilibrium disorders after COVID-19 diagnosis. Of these, 32 patients reported dizziness (94.1%) and 2 (5.9%) reported acute vertigo attacks. Forty-three patients (23.2%) reported tinnitus; 14 (7.6%) reported both tinnitus and equilibrium disorders. Conclusion: This study suggests that the presence of subjective otoneurological symptoms such as tinnitus and balance disorders can affect COVID-19 patients; further studies are necessary to investigate the prevalence and pathophysiological mechanisms underlying these subjective symptoms in COVID-19 patients.
- Published
- 2020
8. Impact of COVID-19 on otolaryngology in Italy: a commentary from the COVID-19 task force of the young otolaryngologists of the Italian Society of Otolaryngology
- Author
-
Ralli, Massimo, Giuditta, Mannelli, Marco, Bonali, Pasquale, Capasso, Pierre, Guarino, Valeria, Iannini, Niccolò, Mevio, Gennaro, Russo, Alfonso, Scarpa, Giacomo, Spinato, Davide, Topazio, and Gabriele, Molteni
- Subjects
SARS-CoV-2 ,COVID-19 ,Otolaryngology Head and Neck Surgery ,Italy - Published
- 2020
9. Supracricoid laryngectomy for recurrent laryngeal cancer after chemoradiotherapy: a systematic review and meta-analysis
- Author
-
Davide Topazio, Carlo Antonio Leone, Russo G, and Pasquale Capasso
- Subjects
Larynx ,medicine.medical_specialty ,medicine.medical_treatment ,Laryngectomy ,Review ,Cricoid Cartilage ,03 medical and health sciences ,0302 clinical medicine ,Laryngeal cancer ,Recurrence ,Otology ,Percutaneous endoscopic gastrostomy ,Humans ,Medicine ,030223 otorhinolaryngology ,Laryngeal Neoplasms ,Radiotherapy ,business.industry ,Supracricoid Laryngectomy ,Cancer ,Chemoradiotherapy ,medicine.disease ,Supracricoid laryngectomy ,Surgery ,Radiation therapy ,Meta-analysis ,General Energy ,medicine.anatomical_structure ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Neoplasm Recurrence, Local ,business - Abstract
La recidiva e la persistenza del cancro della laringe dopo radioterapia rappresentano eventi insidiosi, i cui tassi di incidenza variano dal 13% al 36%. Lintervento di laringectomia sopracricoidea (LSC), con cricoioidopessia (CIP) o cricoioidoepiglottopessia (CIEP), è in grado di garantire risultati oncologici e funzionali affidabili per i pazienti selezionati affetti da carcinoma glottico o sopraglottico, sia in caso di neoplasia primitiva che di recidiva. La presente metanalisi ha lo scopo di valutare i parametri oncologici e funzionali nei pazienti trattati con LSC per recidiva di carcinoma squamocellulare della laringe dopo fallimento di radioterapia. La ricerca è stata effettuata sui databases MEDLINE, PubMed ed EMBASE (da gennaio 1990 a dicembre 2015, solo in lingua inglese). Per la metanalisi è stato impiegato il metodo DerSimonian e Laird con effetto midex random; leterogeneicità è stata misurata mediante I. Sono stati inclusi nella ricerca 276 articoli, tra i quali ne sono stati selezionati 14 per la metanalisi, per un totale di 291 pazienti. Lanalisi statistica ha mostrato una sopravvivenza globale (OS) a 5 anni del 80,2% (IC 0,719-0,885; I= 62%; p = 0,003) e una sopravvivenza libera da malattia (DFS) a 5 anni del 89,5% (IC 0,838-0,952; I= 52%; p = 0,022). Le indicazioni chirurgiche per una LSC dopo fallimento di radioterapia non cambiano rispetto a quelle adottate per pazienti con tumore primitivo. Pertanto, è stato ipotizzato che lattenta valutazione dellestensione del tumore, in caso di recidiva, potrebbe essere responsabile dellalto tasso di OS e DFS a 5 anni. Per quanto riguarda i parametri di valutazione funzionale precoce postoperatoria, il tempo medio di decannulazione è stato di 35,6 giorni (IC 24,3-46,9; I= 95%; p < 0,001), mentre il tempo medio di rimozione del sondino naso-gastrico (SNG) o della gastrostrostomia percutanea endoscopica (PEG) è stato di 28,3 giorni (IC 22,7-33,8; I= 86%; p
- Published
- 2016
10. Systemic Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation
- Author
-
James P. Di Santo, Helene Strick-Marchand, Yan Li, Anne Puel, Armanda Casrouge, Hans Yssel, Lucia Anna Muscarella, Xavier Norel, Eyal David, Davide Topazio, Nicolas Serafini, Lionel Le Bourhis, Jacinta Bustamante, Ido Amit, Jean-Laurent Casanova, Jean-Michel Sallenave, Ai Ing Lim, Rudi W. Hendriks, Matthieu Allez, Silvia Lopez-Lastra, Thomas Graf, Lars Rogge, Paolo Graziano, Franziska Paul, Guillemette Masse-Ranson, Ralph Stadhouders, Laura Surace, Roberto Cocchi, Université Paris Diderot - Paris 7 (UPD7), Immunité Innée - Innate Immunity, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11), Barcelona Institute of Science and Technology (BIST), Weizmann Institute of Science [Rehovot, Israël], Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Universitaire d'Hématologie (IUH), Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Casa Sollievo della Sofferenza [San Giovanni Rotondo] (IRCCS), Immunorégulation, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Saint-Louis, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Erasmus University Medical Center [Rotterdam] (Erasmus MC), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller University [New York], Howard Hughes Medical Institute (HHMI), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris], We thank all the members of Innate Immunity Unit for helpful discussions, the Centre de Recherche Translationnelle, F. Pala and O. Fiquet (Institut Pasteur), and A. Sparaneo (Casa Sollievo della Sofferenza) for technical assistance. A.I.L. is a scholar in Pasteur-Paris University (PPU) International PhD program and supported by FP7 under grant agreement 317057 (HOMIN) and the Fondation ARC. R.S. was supported by EMBO (ALTF 1201-2014) and Marie Curie (H2020-MSCA-IF-2014). Other support included grants from the Institut Pasteur, Inserm, Laboratoire d’Excellence REVIVE (ANR-10-LBX-73), and FP7 under grant agreement HEALTH-F3-2012-305578 (PathCO) and 317057 (HOMIN). J.P.D. is a founder of AXENIS and a member of its advisory board., ANR-10-LABX-0073,REVIVE,Stem Cells in Regenerative Biology and Medicine(2010), European Project: 317057,EC:FP7:PEOPLE,FP7-PEOPLE-2012-ITN,HOMIN(2013), European Project: 305578,EC:FP7:HEALTH,FP7-HEALTH-2012-INNOVATION-1,PATHCO(2012), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut Pasteur [Paris] (IP), Pulmonary Medicine, Di Santo, James, Laboratoires d'excellence - Stem Cells in Regenerative Biology and Medicine - - REVIVE2010 - ANR-10-LABX-0073 - LABX - VALID, Host-microbe interactions in health and disease. Interface with the immune system - HOMIN - - EC:FP7:PEOPLE2013-04-01 - 2017-03-31 - 317057 - VALID, Pathogen COinfection:HIV, Tuberculosis, Malaria and Hepatitis C virus - PATHCO - - EC:FP7:HEALTH2012-11-01 - 2017-10-31 - 305578 - VALID, Université Paris Diderot - Paris 7 (UPD7)-Université Paris 13 (UP13)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Immunité Innée, Weizmann Institute of Science, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), IRCCS 'Casa Sollievo della Soffernza', Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), St Giles laboratory of Human Genetics and Infectious Diseases, rockefeller university, Howard Hughes Medical Institute, Albert Einstein College of Medicine, and ANR-10-LABX-0073/10-LABX-0073,REVIVE,Stem Cells in Regenerative Biology and Medicine(2010)
- Subjects
0301 basic medicine ,Transcription, Genetic ,Cellular differentiation ,Antigens, CD34 ,Single cell cloning ,Mice ,0302 clinical medicine ,RAR-related orphan receptor gamma ,Interferon ,Humanized mice ,Cytotoxic T cell ,Lymphocytes ,skin and connective tissue diseases ,Lung ,Orphan receptor ,Stem Cells ,Lymphopoiesis ,Interleukin-17 ,Innate lymphoid cell ,Cell Differentiation ,Fetal Blood ,3. Good health ,Cell biology ,Proto-Oncogene Proteins c-kit ,Liver ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Cytokines ,medicine.drug ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,Lymphoid Tissue ,Innate lymphoid cells ,Biology ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Fetus ,medicine ,Transcription factors ,Animals ,Humans ,Cell Lineage ,development ,Immunity, Innate ,Signaling ,body regions ,Retinoic acid receptor ,030104 developmental biology ,Cell fate ,Immunology ,030215 immunology - Abstract
Innate lymphoid cells (ILCs) represent innate versions of T helper and cytotoxic T cells that differentiate from committed ILC precursors (ILCPs). How ILCPs give rise to mature tissue-resident ILCs remains unclear. Here, we identify circulating and tissue ILCPs in humans that fail to express the transcription factors and cytokine outputs of mature ILCs but have these signature loci in an epigenetically poised configuration. Human ILCPs robustly generate all ILC subsets in vitro and in vivo. While human ILCPs express low levels of retinoic acid receptor (RAR)-related orphan receptor C (RORC) transcripts, these cells are found in RORC-deficient patients and retain potential for EOMES+ natural killer (NK) cells, interferon gamma-positive (IFN-γ+) ILC1s, interleukin (IL)-13+ ILC2s, and for IL-22+, but not for IL-17A+ ILC3s. Our results support a model of tissue ILC differentiation ("ILC-poiesis"), whereby diverse ILC subsets are generated in situ from systemically distributed ILCPs in response to local environmental signals. A.I.L. is a scholar in Pasteur-Paris University (PPU) International PhD program and supported by FP7 under grant agreement 317057 (HOMIN) and the Fondation ARC. R.S. was supported by EMBO (ALTF 1201-2014) and Marie Curie (H2020-MSCA-IF-2014). Other support included grants from the Institut Pasteur, Inserm, Laboratoire d'Excellence REVIVE (ANR-10-LBX-73), and FP7 under grant agreement HEALTH-F3-2012-305578 (PathCO) and 317057 (HOMIN). J.P.D. is a founder of AXENIS and a member of its advisory board.
- Published
- 2017
- Full Text
- View/download PDF
11. Unusual postrhinoplasty complication: nasal dorsum cyst
- Author
-
Stefano Di Girolamo, Davide Topazio, Pier Giorgio Giacomini, Roberta Di Mauro, S. Mocella, and Matteo Chimenti
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Case Report ,Mucous membrane of nose ,General Medicine ,lcsh:Otorhinolaryngology ,medicine.disease ,Nasal bone ,lcsh:RF1-547 ,Vomer bone ,Surgery ,Rhinoplasty ,Settore MED/31 - Otorinolaringoiatria ,medicine ,Cyst ,Nasal dorsum ,Foreign body ,Complication ,business - Abstract
Among all the possible complications of aesthetic rhinoplasty, a rare one is the development of cystic masses on the nasal dorsum: several theories suggest that cysts develop commonly by entrapment of nasal mucosa in the subcutaneous space, but they can also originate from foreign body reactions. This report deals with two cases of nasal dorsum cysts with different pathogenesis: both patients had undergone aesthetic rhinoplasty in the past (26 years ago and 14 years ago, resp.). Both cystic masses were removed via a direct open approach and nasal reconstruction was performed successfully with autologous vomer bone. The pathologic investigations showed a foreign body inclusion cyst associated with latex rubber in the first case and a sequestration of a mucosal-lined nasal bone was not removed at the time of primary rhinoplasty in the second case. A brief review of the literature focuses on the pathophysiology and treatment options for nasal dorsal cysts following aesthetic rhinoplasty.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.